Transplacental transfer of spiramycin was investigated in a rhesus monkey model to study whether the antibiotic reaches therapeutic levels in the fetus. Spiramycin concentrations were measured by bioassay and high-performance liquid chromatography. Pharmacokinetic parameters were determined for bioactive spiramycin as measured by the bioassay. Pharmacokinetic pilot studies showed that spiramycin distribution follows a two-compartment model in rhesus monkeys. Following a single intravenous dose of 50 or 250 mg, dose-dependent kinetics were observed. At a dose of 50 mg, 10Wo of the dose was excreted unchanged in the urine. At the higher dose of 250 mg, an oliguric effect was observed. Spiramycin concentrations in fetal serum were measured over time while the maternal concentration was maintained at a constant level. During a 5-h experiment, a maximum fetal-maternal serum ratio of 0.27 was found. In three fetuses, concentrations in serum and tissue were measured following intravenous administration of 50 mg of spiramycin twice daily to the mother for at least 7 days. The fetal-maternal serum ratios were found to be 0.4 to 0.58 after intravenous administration of the final dose of 50 mg to the mother. It appeared that spiramycin accumulated in the soft tissues, especially in the liver and spleen, of both the mother and the fetus. The concentration in placental tissue appeared to be 10 to 20 times that of the concentration in fetal serum. The concentration of spiramycin in amniotic fluid was about five times higher than the concentration in fetal serum. Another important observation was that absolutely no spiramycin was found in the brain.
Spiramycin is a macrolide antibiotic produced by Streptomyces ambofaciens (31) that consists of a complex of three components: spiramycins I, II, and III (43) . Spiramycin is mainly bacteriostatic, affecting a broad range of bacteria, while the parasite Toxoplasma gondii is also susceptible to this antibiotic (22, 43) . The mechanism of action of spiramycin is not precisely known. It is believed that spiramycin inhibits bacterial protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes during translocation (6) .
Spiramycin is effective in vivo for a variety of infections, despite the fact that its levels in serum are often below the MIC for the infecting organisms (39) . This can be explained in part by the ability of spiramycin to achieve concentrations in tissues and cells that are a factor 10-or even more-higher than the corresponding concentration in serum. High concentrations of spiramycin have been found in female pelvic tissues (1) ; respiratory tract (3) , heart, liver, lung, spleen, and kidney (28, 30) tissues; and macrophages (19, 32, 44) . The phenomenon of marked tissue penetration has also been described for the macrolide antibiotic azithromycin (10, 29, 38) . The high intracellular concentrations of these macrolides may explain their good antibiotic activity against susceptible intracellular organisms.
Toxoplasma gondii is such a susceptible obligatory intracellular organism. This parasite can cause severe disorders, such as hydrocephalus, chorioretinitis, and mental retardation in congenitally infected fetuses (35) . Effective treatment is mandatory to reduce the risk of severe disorders.
Data concerning transplacental transfer of spiramycin have been scarce. In 1968, Garin et al. (15) published the results of assays of levels in human umbilical cord and maternal blood after treatment with spiramycin (3 g/day). The levels in umbilical cord blood were half of those in maternal blood. In 1987, Forestier et al. (13) reinvestigated the transplacental passage of spiramycin in humans. At birth, they found a fetal-maternal serum ratio of 0.74. In addition, they examined samples obtained between the 21st and 24th weeks of pregnancy and found a fetal-maternal serum ratio of 0.47. By using an in vitro perfusion model of isolated placental cotyledons, Quentin et al. (33) found a mass transfer during a 1-h experiment of approximately 9% of the maternal circulating concentrations. The concentrations measured in fetal serum do not reach therapeutic levels, i.e., levels that equal the MIC found in vitro for T. gondii (41) . It is possible that effective intracellular concentrations and concentrations in tissue are reached in the fetus, but such data have not been reported. Therefore, a rhesus monkey (Macaca mulatta) model was used to study the transplacental transfer and tissue distribution of spiramycin in the fetus. The consequences of the findings for the treatment of congenital T. gondii infections will be discussed.
MATERUILS AND METHODS
Animals. In total, 12 Table 1 .
Pharmacokinetic studies with seven adult, nonpregnant monkeys. Spiramycin (Rovamycine; Rhone-Poulenc, Paris, France) was administered intravenously (i.v.) because coadministration with food can reduce bioavailability by 50% (14) . Dose finding experiments were performed with seven monkeys, Al to A7. Monkeys Al, A2, and A3 were given a single i.v. dose of 50 mg. The concentrations in serum dropped below the detection limit 6 h after administration of the 50-mg dose. The dose for monkeys A4, AS, and A6 was increased to 250 mg to enable measurement of detectable concentrations in serum for a longer time. Monkey A7 was given a loading dose of 1.75 mg of spiramycin per kg, followed by continuous infusion of 0.1 mg/kg/min to achieve a constant level in serum of approximately 3.0 to 3.5 ,ug/ml. A level of 3.0 to 3.5 ,ug/ml in serum was chosen because this concentration is normally achieved in humans given spiramycin to treat T. gondii infections (22, 43 Collection of samples. Spiramycin was administered in glucose isotonic solution via the vena saphena, and blood samples were taken from the vena jugularis. The blood vessel was cannulated with a heparinized catheter and connected to a three-way stopcock (Viggo, Helsingborg, Sweden), and samples of 2 to 3 ml of blood were collected. The fluid balance was maintained by replacing the blood with a physiological salt solution.
Samples of 0.5 ml of fetal blood were collected from a blood vessel that interconnects the two placental lobes that are present physiologically in this monkey species, exactly as previously described (37) . In brief, an interplacental blood vessel was visualized by illumination of the uterus with two sterile lamps. After careful incision of the uterus wall and the decidua, the interplacental blood vessel, which is of fetal origin, was exposed. The vessel was cannulated with a catheter, and the samples were collected. The blood was replaced with a physiological salt solution to maintain the fluid balance.
During the transplacental transfer experiment, blood from the mother, blood from the fetus, and amniotic fluid samples were collected at serial time intervals (see Table 2 ). From monkey Al, urine samples were collected over 0 to 4, 4 to 8, and 8 to 24 h. At more regular time intervals, urine samples were also collected from monkeys A2, A3, A5, and A6. In the latter cases, urine production was stimulated by 3 administering g of mannitol per h ( Table 2 ). The urine volume was measured, and an aliquot was kept for determination of the spiramycin concentration.
At the end of the experiment, baby monkeys B3, B4, and B5 were delivered by cesarean section and immediately sacrificed. The hearts, livers, spleens, brains, and placentas were collected to determine the spiramycin concentrations.
Determination of antibiotic concentrations. Pure spiramycin was kindly provided by Rhone Poulenc, Centre de recherches de Vitry, Alfortville, France. According to the manufacturer, the spiramycin used (lot no. RP5337) contained 90.0% spiramycin I, 0.5% spiramycin II, and 6.3% spiramycin III as determined by high-performance liquid chromatography (HPLC). methanol and 80% physiological salt solution. Standards of 10, 5, 2.5, 1.0, 0.5, 0.25, and 0.1 ,ug/ml were prepared from the stock solution by dilution with physiological salt. A negative control of physiological salt with 0.1% methanol did not inhibit S. lutea growth. The sensitivity of the assay was 0.1 ,ug/ml. The bioassay was linear in the concentration range between 0.25 and 10 ,ug/ml. Intraday and interday coefficients of variation were found to be 2.0 and 2.6% for 10 ,ug/ml, 1.5 and 2.7% for 5 ug/ml, 1.7 and 0.7% for 2.5 ,ug/ml, 3.8 and 5.7% for 1.0 ,ug/ml, 3.4 and 5.2% for 0.5 ,ug/ml, 3.7 and 3.8% for 0.25 jig/ml, and 5.1 and 4.3% for 0.1 ,ug/ml, respectively.
Determination of spiramycin by HPLC was performed on LiChrosorb CP Spher C18 (25 cm by 4.6 mm [inside diameter]) with a solvent of 4 g of H3PO4-0.5 g of tetramethylammonium chloride in 500 ml of water mixed with 500 ml of acetonitrile with UV detection at 233 nm and operation at a temperature of 23°C (27) . The quantitation level of the HPLC was 0.1 ,ug/ml. The intraday and interday coefficients of variation were found to be 2.1 and 3.0%, respectively.
Preparation of samples. Tissue samples were homogenized in physiological salt solution (4 mlIg [wet weight] of tissue) with an Ultraturax apparatus (Ystral GmbH, Dottingen, Germany). The crude homogenate was pelleted by 20 min of centrifugation at 1,000 x g. The supernatant was used for the bioassay and HPLC determination. The supernatants and serum samples were kept at -20°C until determination. After thawing, 100 ,ll of the supernatant, serum sample, or urine sample was tested in the bioassay. The samples were diluted with distilled water if necessary.
For (17) . Renal clearance was estimated by the total-excretion method, in which the cumulative amount of spiramycin excreted in 24 h into the urine was used. Curve fitting was done by least-squares nonlinear regression analysis, in which data were reciprocally weighted (1/C2), with the aid of the PCNONLIN computer program (26) . RESULTS Determination of spiramycin. In two experiments (monkeys Al and A4), levels of total spiramycin (I, II, and III) in serum were determined by both bioassay and HPLC. The results found by both detection methods were roughly similar for those serum samples that were collected within 60 min after administration of the dose. For serum samples that were collected after 60 min, the bioassay gave higher concentrations than did HPLC (Table 3) .
Examination of spiramycin concentrations in serum by HPLC revealed that mainly component I was measured (93 to 95%). The concentration of spiramycin II was below the quantitation level. Thus, the remaining 5 to 7% was mainly component III.
Dose-finding experiments. Single-dose kinetics were determined after administration of 50 or 250 mg of spiramycin to Table 5 ). At the end of the experiment, the kinetics of monkey lose of 250 mg. A B3 differed slightly from the kinetics of monkey B2. The proximately 16.5 h concentration of spiramycin in serum increased in the mother, decreased to 6.8 whereas the fetal concentration decreased (Fig. 3) because the tol to monkey A5 fetus most probably died after collection of the blood sample at [yto 0.046 ml/min 4 h. was found. A low After studying placental transfer of spiramycin at a constant level in maternal serum, transfer was studied in monkeys B4 and B5 after a single dose of 50 mg. Prior to the experiment, the monkeys received 50 mg of spiramycin i.v. twice daily for 24 days. The results for monkey B4 are presented in Fig. 4 . A trough level of 0.14 ,ug/ml was found for the fetus. This was 58% of the corresponding maternal concentration (0.24 p,g/ ml). The concentration in fetal serum increased slightly, to about 0.30 jig/ml, and remained constant for 3 h. The transfer experiment was terminated after 3 h, and an autopsy of fetus B4 was performed. Spiramycin concentrations were determined in fetal tissues. The results are presented in Fig. 5 . High spiramycin concentrations were found in the spleen (19 times the concentration in serum), liver (12 times the concentration in serum), and placenta (10 times the concentration in serum). The concentration in the amniotic fluid was relatively steady; 3 h after administration of the final dose, the concentration in amniotic fluid was four times the concentration in fetal serum, but compared with the predose concentration in the amniotic 5 6 , fluid, the concentration was hardly raised. No detectable 5 6 7 concentration of spiramycin was found in the brain. Comparable concentrations in tissue were also found for n monkey A3 serum monkey B5 (Fig. 6) nulation and the concentrations in serum measured in the be more potent than component I, which is not logical. The experiment were not representative.
difference between the bioassay and the HPLC results may also mean that a bioactive metabolite that is formed slowly over DISCUSSION time is measured. This view is supported by the dose-dependent kinetics observed, indicating the likelihood of formation As determined by HPLC, 93 to 95% of the concentration of congenital T gondii infections (36) .
the bioassay and HPLC were in agreement for the serum
The distribution of spiramycin, as measured with the bioassamples obtained within 1 h after administration of the dose. say, in rhesus monkeys follows a two-compartment model, as For serum samples collected after 1 h, the bioassay gave higher has been found in humans (21, 22) . The kinetics appear to be concentrations than did HPLC. The presence of very low dose dependent, probably as a result of saturable-drug metabconcentrations of components II and III might explain the olism. Although less obvious than in rhesus monkeys, dosediscrepancy found between the bioassay and HPLC results. It dependent disposition has also been reported for humans might be possible that components II and III, which cannot be (14) .
detected by HPLC at very low concentrations, are biologically
The urinary excretion of 10% found at a dose of 50 mg in active and are therefore measured by the microbiological rhesus monkeys is identical to the 5 to 15% reported for assay. This implies, however, that components II and III would humans (22, 23) . The renal clearance (15 ± 4 ml/min) is on the order of the glomerular filtration rate of rhesus monkeys (4). Since stimulation of urine production by mannitol did not influence renal clearance, passive reabsorption can be excluded. It seems likely that renal excretion of spiramycin occurs only through glomerular filtration. Remarkable was the acute oliguric effect observed at the high dose of 250 mg. This phenomenon may explain the low excretion at 250 mg. Several drugs have been reported to cause renal failure (2, 5, 9) . Renal failure due to the use of spiramycin or other macrolides has not been reported. Since monkeys A4, A5, and A6 were not sacrificed after the experiment, histological examination of the kidneys was not possible.
The serum elimination half-life of spiramycin in rhesus monkeys was found to be 2 h at a dose of 50 mg. As expected for small animals, this is lower than the value of 5 h found in human volunteers after i.v. administration (14) and the value of 3.8 h reported by Kavi et al. (21) after oral administration.
Studies of the transplacental transfer of spiramycin in humans are poorly documented (13, 15) crease, as found for monkeys B2, B3, and B4. In fact, the fetal-maternal ratio increased to 0.58 in monkey B4, which was given spiramycin for at least 3 weeks. Similar ratios have been found in humans who had been treated for several weeks (13, 15) . These data support system hysteresis, indicating that distribution of spiramycin to the fetus takes longer during the first hours after administration of the antibiotic. Tissue and cell distribution probably gradually increases until the tissues and cells become saturated. The results of MacFarlane et al. (24) , who found that maximum concentrations of spiramycin in tissue are achieved after 7 days of treatment, support this. Therefore, concentrations in tissue were determined after at least 7 days of treatment (monkeys B3, B4, and B5). Our findings support the results of MacFarlane et al. (24) . Drug concentrations in the tissues of monkeys B4 and B5, which were treated for 24 days, were not essentially different from drug concentrations in the tissues of monkey B3, which was treated for 1 week. However, it cannot be concluded from these results whether the maximum levels in tissue are achieved earlier, i.e., before 7 days of treatment.
In rhesus monkeys, as in humans (24) and rats (40) , high concentrations of spiramycin are found mainly in tissues such as the liver and spleen. The mechanism by which such high and long-lasting concentrations in tissue are achieved has not observations lead to the assumption that phagocytes deliver the antibiotic to cells through uptake, transport, and subsequent release into tissues (18, 25) . A similar mechanism may be assumed for spiramycin, since high concentrations of the antibiotic have been found in macrophages (19, 32, 44) . Osono and Umezawa (28) have suggested that the levels of spiramycin in tissue are long lasting compared with those of other macrolides because spiramycin is less easily metabolized. Rapid uptake of spiramycin by tissues from serum and slow redistribution from tissues to serum may be another explanation for the long-lasting concentrations in tissue. High concentrations have also been found in the placenta. The finding that concentrations in maternal serum are higher than the concentrations in fetal serum may indicate that the placenta functions as a clearance organ or as a barrier. More research is needed for better insight into the process of transplacental transfer of spiramycin. In vitro studies with isolated placental cotyledons are in progress. Penetration of spiramycin into cerebrospinal fluid is reported to be poor, but there is little documented evidence (16, 42) . In our study, the concentration of spiramycin in the brain was below the detection limit of the bioassay. Since damage of the fetal brain is the most severe consequence, treatment of congenital T. gondii infection with spiramycin will be ineffective. It is not clear whether the levels reached in tissues other than the brain are therapeutic. Several investigators have reported concentrations of spiramycin that were effective against T. gondii in vitro. Truong et al. (41) found a minimal inhibitory effect at an intracellular concentration of 10 ,ug/g of tissue. In their in vitro cell culture, the corresponding extracellular concentration was 110 ,ug/ml. Chamberland et al. (7) found that a concentration of 20 ,ug/ml had only limited activity (50% inhibition) against T. gondii in vitro. Although Derouin et al. (11) reported that inhibition of Toxoplasma growth in cell culture was already observed at a concentration of 1 ,ug/ml, a maximum effect was only achieved at a drug concentration of 250 ,ug/ml. Such high extracellular concentrations of 200 (20) and 246 (8) pfg/ml have been found to inhibit the incorporation of [3H]uracil by T. gondii tachyzoites in infected cells but had no significant killing effect. The corresponding intracellular spiramycin concentrations, however, are not exactly known.
Nevertheless, it is difficult to compare the in vitro situation with the in vivo one. Whether the concentrations found in tissue are effective in a congenitally infected fetus needs further investigation. Therefore, we have developed a rhesus monkey model for congenital T. gondii infections. The effectiveness of spiramycin has been investigated in this model (36) .
